EYPT
EyePoint Pharmaceuticals, Inc.NASDAQHealthcare$13.40+2.92%ClosedMarket Cap: $1.12B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
3.63
P/S
35.64
EV/EBITDA
-4.33
DCF Value
$-2.89
FCF Yield
-21.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
93.4%
Operating Margin
-776.0%
Net Margin
-739.4%
ROE
-88.3%
ROA
-63.7%
ROIC
-74.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $620.0K | 39.5% | $-70.3M | $-67.6M | $-0.81 | — |
| FY 2025 | $31.4M | 93.4% | $-243.4M | $-232.0M | $-3.17 | — |
| Q3 2025 | $966.0K | 25.4% | $-62.0M | $-59.7M | $-0.85 | — |
| Q2 2025 | $5.3M | 96.9% | $-62.2M | $-59.4M | $-0.85 | — |
| Q1 2025 | $24.5M | 96.7% | $-48.8M | $-45.2M | $-0.65 | — |
| Q4 2024 | $11.6M | 93.0% | $-45.2M | $-41.4M | $-0.64 | — |
| FY 2024 | $43.3M | 91.4% | $-145.9M | $-130.9M | $-2.32 | — |
| Q3 2024 | $10.5M | 93.0% | $-32.7M | $-29.4M | $-0.54 | — |
| Q2 2024 | $9.5M | 85.2% | $-34.5M | $-30.8M | $-0.58 | — |
| Q1 2024 | $11.7M | 93.5% | $-33.3M | $-29.3M | $-0.55 | — |
| Q4 2023 | $14.0M | 92.9% | $-16.4M | $-14.1M | $-0.33 | — |
| FY 2023 | $46.0M | 89.9% | $-75.1M | $-70.8M | $-1.82 | — |